Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors

to manufacture and pharmacological formulation, and we have successfully produced sufficient quantities for initial clinical trials."

Vion scientists Caroline Clairmont, Ph.D. and Li-mou Zheng, Ph.D. also reported new preclinical data showing the safety of VNP20009 in non-human primate models. Previous studies in mice have demonstrated that VNP20009 is more than 10,000 times less toxic than the wild-type Salmonella strain from which it is developed. Additionally, the studies showed that the TAPET bacteria were rapidly cleared from the blood to undetectable levels within 24 hours. New research reported at AACR showed that VNP20009 has no toxic effect when administered to cynomolgous monkeys at very high doses (109 cfu/monkey), which would be toxic using wild-type Salmonella. Moreover, the bacterium is not shed in the animals' feces or urine, and is rapidly cleared from the blood and from other tissues over extended periods of time.

A further report at AACR by Vion scientists showed VNP20009's ability to inhibit the growth of both primary tumors and metastases. VNP20009, injected intravenously into tumor-bearing mice, accumulated and proliferated within tumor tissue at a rate at least 500 times higher than it did in liver, the tissue of second greatest accumulation. This selectivity for tumors was observed in a variety of tumor types, including mouse melanoma, and human melanoma, colon, lung, prostate, and breast tumors transplanted into mice. In addition, the researchers demonstrated that VNP20009 inhibited the growth of lung metastases in models of metastatic melanoma and prolonged the life span of animals treated with the TAPET organisms.

"These new findings further support Vion's position that TAPET organisms should be safe for use in humans and offer considerable potential as a new approach to the treatment of cancer," said Dr. Ivan King, vice president of biology. "Our research has shown TAPET to have a wide ranging ability t

Contact: Joan Kureczka
Kureczka/Martin Associates

Page: 1 2 3

Related biology news :

1. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
2. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
3. Study Demonstrates High Conservation Potential Of Logged Rainforest
4. First glimpse of DNA binding to viral enzyme
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. 2nd media alert First Scientific Conference on Childhood Leukaemia
7. First International Scientific Conference on Childhood Leukaemia
8. First ever standards linking climate change, biodiversity and poverty seek global peer review
9. First genetic comparison of purebred domestic dogs produces surprises
10. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
11. First target for childhood malaria vaccine

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: